BAY-1436032 is a potent, orally bioavailable small molecule inhibitor that selectively targets pan-mutant IDH1 enzymes. It is utilized in preclinical research to investigate mutant IDH1-driven mechanisms in cancers such as glioma, with studies demonstrating its activity in both cellular assays and in vivo models.